Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01077700 | Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia | PHASE2 | COMPLETED | 214 | — | — | Mar 1, 2010 | Jul 1, 2011 | Jun 6, 2018 | 24 | United States |
| Arm | Type | Description |
|---|---|---|
| ABT-288 Dose 1 | EXPERIMENTAL | low dose of ABT-288 |
| ABT-288 Dose 2 | EXPERIMENTAL | high dose of ABT-288 |
| Sugar Pill | PLACEBO_COMPARATOR | inactive substance |
| Name | Type | Description |
|---|---|---|
| ABT-288 Low Dose | DRUG | - |
| Placebo | DRUG | inactive substance |
| ABT-288 High Dose | DRUG | - |
Inclusion Criteria: * Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview. * Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial S...